Although increasing the reimbursement rate for cancer screening tests does not consistently improve the likelihood of Medicaid beneficiaries being screened for cancer, raising the rate of reimbursement for office visits does consistently increase the likelihood that they will be screened for cancer, including breast or prostate cancer, according to results of a new analysis of Medicaid claims and enrollment data.
Madrid, Spain—Final results from the CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial show that dual HER2 blockade with the combination of pertuzumab and trastuzumab plus chemotherapy extended overall survival (OS) by almost 16 months compared with trastuzumab plus chemotherapy alone in patients with HER2-positive metastatic breast cancer. This should become the new standard of care for patients with metastatic HER2 disease, according to the study investigators, who presented their results at the 2014 European Society for Medical Oncology (ESMO) Congress.
Madrid, Spain—Combination therapy with a BRAF inhibitor and a MEK inhibitor improves survival outcomes in patients with advanced BRAF-mutated melanoma, based on results of 2 phase 3 clinical trials presented at the 2014 European Society for Medical Oncology Congress.
Madrid, Spain—The positive results from 2 studies raised speculation about a possible resurrection of the breast cancer indication for bevacizumab, as reported at the 2014 European Society for Medical Oncology Congress.
Madrid, Spain—Continuing an EGFR inhibitor after acquired resistance does not slow the progression of advanced non–small-cell lung cancer (NSCLC) in patients receiving chemotherapy, according to a report presented at the 2014 European Society for Medical Oncology (ESMO) Congress. However, extending anti-EGFR therapy with erlotinib beyond disease progression may be beneficial, according to a second report presented at the meeting.
A survey of patients with cancer and caregivers about the benefits they would like Medicare to cover in their last 6 months of life uncovered large gaps with the benefits that Medicare currently offers.
The US Department of Health and Human Services (HHS) has responded to the chorus of voices calling for less complex rules governing electronic health records (EHRs) by not adopting the Voluntary 2015 Edition Electronic Health Record Certification Criteria. In its final rule, released in September 2014, the Office of the National Coordinator for Health Information Technology has instead included 10 optional and 2 revised certification criteria.
San Francisco, CA—A new GP2 peptide vaccine was safe and reduced the rate of breast cancer recurrence in women with high-risk breast cancer in a phase 2 clinical trial. The vaccine was particularly effective in reducing recurrence in women with HER2 overexpression, reported Elizabeth A. Mittendorf, MD, PhD, Assistant Professor of Surgical Oncology, M.D. Anderson Cancer Center, Houston, at the 2014 Breast Cancer Symposium.
San Francisco, CA—Preoperative breast magnetic resonance imaging (MRI) failed to influence clinical management in any subgroup of 257 patients with breast cancer, according to the results of a retrospective review that led one cancer center to discontinue the practice.
San Francisco, CA—A second study adds to the body of evidence that including a luteinizing hormone-releasing hormone (LHRH) agonist with chemotherapy as treatment for breast cancer increases a younger woman’s likelihood of becoming pregnant. The new data, which were presented at the 2014 Breast Cancer Symposium, come from a long-term follow-up of the phase 3 clinical trial known as PROMISE-GIM6.
Page 1 of 4
Results 1 - 10 of 33
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology